Loading organizations...
§ Private Profile · New York City, NY, USA
Consumer health company developing supplements using natural compounds for long-term health, focused on aging research and cellular function.
Elysium Health has raised $45.0M across 2 funding rounds.
Key people at Elysium Health.
Elysium Health has raised $45.0M in total across 2 funding rounds.
New York-based Elysium Health develops direct-to-consumer dietary supplements and consumer health products focused on cellular aging, metabolic function, and longevity research. The company formulates its commercial product portfolio using natural compounds designed to support long-term human health, specifically targeting NAD+ levels and sirtuin activation pathways through its flagship daily supplement, Basis. To translate complex scientific advancements into accessible consumer therapeutics, the enterprise collaborates extensively with leading academic institutions like the Massachusetts Institute of Technology (MIT) and the University of Oxford. The organization is backed by prominent venture capital firms including General Catalyst, Breyer Capital, and Morningside Ventures, having raised approximately $71 million in total equity funding to scale its ongoing clinical research and development operations. Elysium Health was founded in 2014 by co-founders Eric Marcotulli and Dan Alminana, alongside chief scientist Dr. Leonard Guarente.
Key people at Elysium Health.
Elysium Health has raised $45.0M across 2 funding rounds. Most recently, it raised $40.0M Elysium - Series C in December 2019.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 23, 2019 | $40M Series C | Giammaria Giuliani | Breyer Capital, General Catalyst, Mayo Clinic, Morningside Ventures | Announced |
| Jun 29, 2017 | $5M Debt Financing | Silicon Valley Bank | — | Announced |
Elysium Health is a consumer health company dedicated to translating scientific advancements in aging research into accessible products and technologies.[1][2][3] It develops clinically validated supplements like Basis (which replenishes NAD+ to combat cellular aging and boost energy) and Matter (a micronutrient complex for brain aging, developed with Oxford based on the VITACOG study), targeting individuals seeking proactive health solutions for longevity and wellness.[4] The company serves everyday consumers through direct-to-consumer sales, addressing multi-factor aging problems like cellular decline and cognitive health with a science-first approach backed by partnerships with MIT, Oxford, Yale, and a Scientific Advisory Board including eight Nobel laureates.[1][4] Growth is evidenced by a $40 million Series C funding round in prior years to expand its product pipeline, customer base, and clinical trials.[7]
Elysium Health emerged from pioneering aging research starting in 1982, when co-founder and chief scientist Dr. Leonard Guarente, fresh from his Harvard Ph.D., established a lab at MIT to study genetic and molecular causes of aging using baker's yeast (Saccharomyces cerevisiae).[2] Guarente's breakthroughs on sirtuins and NAD+—key molecules in cellular health—laid the groundwork for products like Basis.[1][2] In recent years, he partnered with CEO Eric Marcotulli (from tech and VC backgrounds) and co-founder Dan Alminana to commercialize this science, founding Elysium to make research directly accessible to consumers amid accelerating discoveries like the hallmarks of aging and potential reversal mechanisms.[1][2][4] Early traction came from rigorous clinical validation and institutional ties, humanizing the mission to democratize longevity science.[1][7]
Elysium rides the geroscience wave, capitalizing on 20+ years of breakthroughs like sirtuins, NAD+, hallmarks of aging, and early reversal evidence to pioneer proactive, consumer-facing longevity solutions.[1][2] Timing aligns with booming direct-to-consumer health trends, where aging research shifts healthcare from reactive treatment to prevention, fueled by genomic mapping and cellular metabolism insights.[1][2] Market forces like rising demand for science-backed wellness (amid press acclaim and clinical trial momentum) favor Elysium, influencing the ecosystem by setting standards for rigor—collaborating with academia to bridge labs and consumers, potentially redefining health as a daily, accessible practice.[4][7]
Elysium is poised to expand its pipeline with new tests, interventions, and trials, leveraging funding for broader reach in the exploding longevity market.[7] Trends like AI-driven personalized aging tech and regulatory nods for NAD+ therapies will accelerate growth, evolving its influence from niche supplements to ecosystem leader in evidence-based healthspan extension. This builds on its core mission, turning yesterday's yeast lab discoveries into tomorrow's everyday vitality.[1][2]
Elysium Health has raised $45.0M in total across 2 funding rounds.
Elysium Health's investors include Giammaria Giuliani, Breyer Capital, General Catalyst, Mayo Clinic, Morningside Ventures, Silicon Valley Bank.
